|Bid||5.00 x 800|
|Ask||5.25 x 1000|
|Day's range||5.12 - 5.49|
|52-week range||4.04 - 19.63|
|Beta (5Y monthly)||2.09|
|PE ratio (TTM)||N/A|
|Earnings date||28 Apr 2020 - 03 May 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||17.82|
Investors in MacroGenics, Inc. (NASDAQ:MGNX) had a good week, as its shares rose 4.4% to close at US$12.01 following...
MacroGenics, Inc. (NASDAQ:MGNX) shareholders should be happy to see the share price up 23% in the last quarter. But...
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
MacroGenics (MGNX) delivered earnings and revenue surprises of 4.21% and -19.66%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.
MacroGenics (MGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But...
MacroGenics (MGNX) delivered earnings and revenue surprises of 32.29% and -39.74%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of MacroGenics, Inc...
Incyte (INCY) inks a licensing deal with Zai Lab to develop and commercialize INCMGA0012 for hematology and oncology indications in Greater China.
These companies could make a big difference in how the disease is diagnosed and treated. And their stocks could make a big difference for long-term investors.
In 2001 Scott Koenig was appointed CEO of MacroGenics, Inc. (NASDAQ:MGNX). This report will, first, examine the CEO...